We work to map the microbiome and illuminate interactions foundational to the health of humanity.
Location: United States
Employees: 1-10
Total raised: $72.5M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 06.03.2023 | DCVC | dcvc.com/ |
| 30.08.2022 | Kevin M. M... | mcgovernce... |
| 28.07.2024 | Germin8 Ve... | germin8ven... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.05.2026 | Series A | $48M | DCVC |
| 01.07.2024 | - | $12.5M | - |
| 22.06.2023 | Seed | $12M | Uncommon D... |
Mentions in press and media 13
| Date | Title | Description |
| 12.05.2026 | Kanvas Biosciences Secures $48M to Revolutionize Cancer Immunotherapy with Spatial Microbiome Tech | Kanvas Biosciences secures a pivotal $48 million Series A round, boosting total funding to $78 million. This capital fuels accelerated clinical trials for KAN-001, their lead immuno-oncology therapeutic. KAN-001 targets non-responsive cance... |
| 07.05.2026 | Kanvas Biosciences: $48 Million Series A Raised For Microbiome Cancer Therapeutics Platform | Kanvas Biosciences announced it raised a $48 million Series A financing round to advance microbiome therapeutics designed to improve immunotherapy outcomes for cancer patients. The financing was co-led by existing investors DCVC and Lions C... |
| 06.05.2026 | Kanvas Biosciences Raises $48M to Advance Spatial Biology Platform and Immuno-Oncology Trials | What You Should Know Kanvas Biosciences has raised $48M in Series A funding co-led by DCVC and Lions Capital LLC, bringing total funding to $78M. The capital will fund clinical trials for KAN-001, an immuno-oncology drug candidate designed ... |
| 06.05.2026 | Kanvas Biosciences Raises $48M in Series A Funding | Kanvas Biosciences, a Princeton, NJ-based spatial biology company, raised $48M in Series A funding. The round was led by DCVC and Lions Capital LLC. Additional participating investors included Gates Foundation, ATHOS KG, Germin8, Ki Tua Fun... |
| 04.07.2024 | Kanvas Biosciences: Revolutionizing Cancer Treatment with Microbiome-Based Therapies | Kanvas Biosciences, a cutting-edge spatial biology company based in Princeton, NJ, has recently secured an additional $12.5 million in funding to advance its groundbreaking microbiome-based immuno-oncology drug candidates. This latest fundi... |
| 01.07.2024 | Kanvas Biosciences Secures Additional $12.5M | PRINCETON, NJ, Kanvas Biosciences, a full-stack spatial biology company, announced it has raised $12.5 million in additional funding. >> Click here for more funding data on Kanvas Biosciences >> To export Kanvas Biosciences fun... |
| 01.07.2024 | Kanvas Biosciences Secures Additional $12.5M to Advance Its Novel, Microbiome-Based Immuno-oncology Drug Candidates to IND Filing | With $29.5 million in total funding, the company has developed the world's leading spatial biology platform, designed for breakthroughs in drug development, clinical diagnostics, agriculture, and food safety. This proprietary mapping techno... |
| 01.07.2024 | Kanvas Biosciences Secures Additional $12.5M in Funding | Kanvas Biosciences, Princeton, NJ-based spatial biology company, raised additional $12.5M in funding. The round, which brought the total amount to $29.5M, was led by DCVC and Lions Capital LLC, and participation from FemHealth Ventures, Ger... |
| 22.06.2023 | Kanvas Biosciences Raises $12M in Pre-Series A | Kanvas Biosciences, a Monmouth Junction, NJ-based company which specializes in advancing microbiome mapping technology, raised $12M in Pre-Series A funding. The round was led by DCVC with participation from Lions Capital LLC, Cooke LLC, Unc... |
| 22.06.2023 | Kanvas Biosciences Inks $12M Series A Round | PRINCETON, NJ, Kanvas Biosciences, the leader in microbiome mapping technology, announced today a $12 million Pre-Series A funding round. >> Click here for more funding data on Kanvas Biosciences >> To export Kanvas Bioscien... |
Show more